BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Formosa Pharmaceuticals, Inc.

 

Company Info

Name /Formosa Pharmaceuticals, Inc.

Address /8F-6, No. 57, Fuxing N. Rd., Songshan District., Taipei 105, Taiwan

Website /https://www.formosapharma.com

Presenter

Name /Dr. Erick Co, Ph.D.

Title /Chief Executive Officer

Email /erickco@formosapharma.com

Telephone /(Work) +886 2 2755 7659, ext. 18

Fax /+886 2 2755 3023

Mobile /+886 976266515

Company Type

Biotechnology

About the Company

Formosa Pharmaceuticals is a preclinical and early-clinical stage biotech with assets in ophthalmology, oncology, and anti-infectives. Based in Taipei, Taiwan, Formosa Pharmaceuticals has a network of global partners and senior executives with international drug discovery and management experience. TSY0110, a biosimilar of ado-trastuzumab emtansine, is under development and available for partnering/licensing. APP13007, our lead asset for the treatment of post-surgical ocular pain and inflammation, has initiated Phase 3 studies in the United States, and expects to be approved in 2023. Our proprietary APNT drug delivery formulation platform, from which APP13007 was developed, is available for licensing, CDMO services, or co-development.

Brief Description of main products or services

Formosa Pharmaceuticals offers the following assets for partnering, co-development, or regional licensing:

  • TSY-0110
    1. Biosimilar of the antibody-drug conjugate, Kadcyla® for metastatic breast cancer
    2. Planned Phase 1 clinical trials (EU) in 2022
    3. Full-range manufacturing from payload-linker, bioconjugation, and fill-finish with partner, Formosa Laboratories
  • APP13007
    1. Potent steroid-based eyedrop for Inflammation and Pain after Ocular Surgery
    2. Phase 3 clinical studies ongoing in United States
    3. Anticipated approval in 2023
  • APP13002
    1. Antibiotic-based eyedrop for infectious eye diseases
    2. Future potential indication in Blepharitis
    3. Potential as monotherapy or combination
  • APNT nanoparticle formulation platform
    1. Tailored for APIs with poor solubility, the APNT platform enhances the dissolution and distribution, thereby improving bioavailability.
    2. Applicable to topical, inhaler, and oral administration routes
    3. The APNT platform’s characteristics and advantages:
      • Reliable and tunable particle reduction down to sub-100 micron size
      • Stable particle size post-formulation
      • Lower contamination and removable excipients to enable higher concentration
      • Amenable to aseptic filtration
      • Strong patent protection
  • MPT0E028
    1. Novel small-molecule HDAC inhibitor for the treatment of solid tumors and lung fibrosis
    2. Completed Phase 1 in Taiwan
    3. Out-licensed (non-exclusive) to Anbogen Therapeutics (Taiwan) and Joseah Bio (Korea)

Contact Person

Name /Dr. Erick Co, Ph.D.

Email /erickco@formosapharma.com

Phone /(Work) +886 2 2755 7659, ext. 18